Chugai Pharmaceutical Co., Ltd

4519

JP3519400000

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-18 am EDT			5-day change	1st Jan Change
5,983 ^JPY	-1.25%		-5.84%	+12.00%

Jul. 02	Financials lift Japanese shares on rate-hike speculation	RE
Jun. 24	Japan's Nikkei ends choppy session on stronger note	RE

Chugai Pharmaceutical Co., Ltd. Launches New Immunosuppressant Drug

January 13, 2016 at 11:32 am EST

Chugai Pharmaceutical Co. Ltd. launched CellCept powder for oral suspension 31.8%, a new formulation of the immunosuppressant CellCept sapsules 250, indicated for the treatment of refractory rejections after kidney transplant and suppression of rejections after the following organ transplants.

Latest news about Chugai Pharmaceutical Co., Ltd

Financials lift Japanese shares on rate-hike speculation	Jul. 01	RE
Japan's Nikkei ends choppy session on stronger note	Jun. 24	RE
Japan's Nikkei squeezes out gains in choppy session	Jun. 23	RE
Japan's Nikkei rises on US stocks, heavyweight chip shares	Jun. 10	RE
Tech stocks lift Japan's Nikkei on boost from Nvidia's robust outlook	May. 22	RE
Japan's Nikkei drifts sideways as more earnings, US CPI awaited	May. 13	RE
Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation	May. 01	MT
Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	Apr. 25	MT
Chugai Pharmaceutical's Profit Slightly Up in Q1	Apr. 24	MT
Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending December 31, 2024; Provides Dividend Guidance for the Year Ending December 31, 2024	Apr. 24	CI
Japan's Nikkei slips on caution ahead of US inflation data	Apr. 09	RE
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	Mar. 29	MT
Roche's Chugai Wins Japanese Approval for Piasky Injection	Mar. 27	MT
Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy	Mar. 04	MT
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	Feb. 26	MT
Nikkei extends record rally on pharma boost	Feb. 25	RE
Nikkei hits record high as index heavyweights advance	Feb. 25	RE
US Tech Outlook Boost Asian Stock Markets	Feb. 22	MT
Global markets live: Sanofi, ABB, Qualcomm, Roche, Shell...	Feb. 01
Chugai Pharmaceutical’s Profit Down 13% in 2023	Feb. 01	MT
Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024	Feb. 01	CI
From scandal to delisting: Toshiba's long-running crisis	Dec. 19	RE
Jefferies Adjusts Chugai Pharmaceutical’s Price Target to 6,200 Yen From 5,400 Yen, Keeps at Buy	Dec. 14	MT
Transcript : Chugai Pharmaceutical Co., Ltd. - Pre Recorded Special Call	Nov. 27
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	Nov. 27	MT

Chart Chugai Pharmaceutical Co., Ltd

Duration

Period

More charts

Company Profile

Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Chugai Pharmaceutical Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6,059 JPY

Average target price

5,961 JPY

Spread / Average Target

-1.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHUGAI PHARMACEUTICAL CO., LTD	+12.00%	63.66B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.24%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ROCHE HOLDING AG	+13.05%	250B
ASTRAZENECA PLC	+16.17%	247B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals